AI assistant
Esperion Therapeutics, Inc. — Director's Dealing 2021
May 18, 2021
32771_dirs_2021-05-18_63c72277-57b2-4037-8e64-93219d0f0d8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2021-05-17
Reporting Person: Koenig Sheldon L. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-17 | Common Stock | A | 20000 | — | Acquired | 50000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-17 | Stock Option (right to buy) | $20.87 | A | 120000 | Acquired | 2031-05-17 | Common Stock (120000.0) | Direct |
Footnotes
F1: Such awards will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of June 15, 2021 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service
F2: Such options will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of June 15, 2021 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service